Patent intelligence · US
US 10004699
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
Patent details — US 10004699
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 26, 2018
- Expiration
- Jun 21, 2038
- Applicant
- Acurx Pharmaceuticals, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/137, A61K47/10, A61K47/12
Quick answer
US 10004699 (Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse) is held by Acurx Pharmaceuticals, Inc.. Status: granted. Granted Jun 26, 2018. Expires Jun 21, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Acurx Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/137, A61K47/10, A61K47/12, A61K47/14, A61K47/32
More from Acurx Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12036225
Use of ibezapolstat to promote microbiome health
granted -
US 11857629
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 11723885
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
granted -
US 11554114
Methods and compositions for self-regulated release of active pharmaceutical ingredients
granted -
US 11197837
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
granted -
US 11103581
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 11083794
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 11001592
DNA polymerase IIIC inhibitors and use thereof
granted
Frequently asked questions
What is US patent 10004699?
US 10004699 (Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse) is held by Acurx Pharmaceuticals, Inc.. Status: granted. Granted Jun 26, 2018. Expires Jun 21, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10004699?
Acurx Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 28 pharmaceutical patents for this assignee.
When does US 10004699 expire?
Our index shows an expiration date of Jun 21, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.